INBX 8-K: Q3 and nine-month 2025 results press release furnished

Rhea-AI Filing Summary

Inhibrx Biosciences furnished an 8-K to announce it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.

The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act, and will not carry Section 18 liability or be incorporated by reference unless expressly specified.

The filing also includes Exhibit 104, the cover page interactive data file embedded in Inline XBRL.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/13/2025 - 06:00 PM Learn about SEC filing dates

FAQ

What did Inhibrx Biosciences (INBX) announce in this 8-K?

The company furnished a press release with Q3 2025 and nine-month results, included as Exhibit 99.1.

Which period does the INBX press release cover?

The three and nine months ended September 30, 2025.

Is the financial information considered filed or furnished?

It is furnished, not filed, and is not subject to Section 18 liability or incorporation by reference unless specifically stated.

What exhibits are included with the INBX 8-K?

Exhibit 99.1 (press release dated November 14, 2025) and Exhibit 104 (cover page Inline XBRL).

What is the trading symbol and exchange for Inhibrx Biosciences?

Common stock trades under INBX on The Nasdaq Global Market.

When was the 8-K event date for INBX?

November 14, 2025.

Who signed the INBX 8-K?

Kelly Deck, Chief Financial Officer.

FALSE000200791900020079192025-11-142025-11-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

INHIBRX BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)  

Delaware

001-42031

99-0613523

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

11025 N. Torrey Pines Road, Suite 140

La Jolla, CA 92037

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 795-4220

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			INBX			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Item 2.02    Results of Operations and Financial Condition

On November 14, 2025, Inhibrx Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release issued by Inhibrx Biosciences, Inc. on November 14, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2025
			INHIBRX BIOSCIENCES, INC.
			By:			/s/ Kelly Deck
			Name:			Kelly Deck
			Title:			Chief Financial Officer